Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 153987, 10 pages
http://dx.doi.org/10.1155/2015/153987
Research Article

β-Elemene Inhibits Cell Proliferation by Regulating the Expression and Activity of Topoisomerases I and IIα in Human Hepatocarcinoma HepG-2 Cells

1Department of Oncology, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, China
2Department of General Surgery, The First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116011, China
3Department of Pathology, School of Basic Medicine, Dalian Medical University, Dalian, Liaoning 116023, China

Received 26 March 2015; Revised 27 May 2015; Accepted 30 May 2015

Academic Editor: Xin-yuan Guan

Copyright © 2015 Min Gong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. R. Lencioni, X.-P. Chen, L. Dagher, and A. P. Venook, “Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved?” The Oncologist, vol. 15, supplement 4, pp. 42–52, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. B. H. O'Neil and A. P. Venook, “Hepatocellular carcinoma: the role of the North American GI steering committee hepatobiliary task force and the advent of effective drug therapy,” The Oncologist, vol. 12, no. 12, pp. 1425–1432, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. P. Merle and F. Mornex, “Transarterial chemoembolization and conformal radiotherapy for hepatocellular carcinoma,” Cancer/Radiothérapie, vol. 15, no. 1, pp. 69–71, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Song, H. Xu, J. Tang, X. Li, and S. Zhou, “Transcatheter hepatic arterial infusion chemotherapy combined with element emulsion for treatment of primary hepatic carcinoma,” China Pharmaceuticals, vol. 16, no. 16, pp. 23–24, 2007. View at Google Scholar
  5. Q. Q. Li, R. X. Lee, H. Liang, and Y. Zhong, “Anticancer activity of β-elemene and its synthetic analogs in human malignant brain tumor cells,” Anticancer Research, vol. 33, no. 1, pp. 65–76, 2013. View at Google Scholar · View at Scopus
  6. B. Zou, Q. Q. Li, J. Zhao, J. M. Li, C. F. Cuff, and E. Reed, “β-elemene and taxanes synergistically induce cytotoxicity and inhibit proliferation in ovarian cancer and other tumor cells,” Anticancer Research, vol. 33, no. 3, pp. 929–940, 2013. View at Google Scholar · View at Scopus
  7. X.-W. Xu, Z.-Z. Yuan, W.-H. Hu, and X.-K. Wang, “Meta-analysis on elemene injection combined with cisplatin chemotherapeutics in treatment of non-small cell lung cancer,” Zhongguo Zhongyao Zazhi, vol. 38, no. 9, pp. 1430–1437, 2013. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Hu, W. Jin, and P.-M. Yang, “Reversal of resistance to adriamycin in human breast cancer cell line MCF-7/ADM by β-elemene,” Chinese Journal of Oncology, vol. 26, no. 5, pp. 268–270, 2004. View at Google Scholar · View at Scopus
  9. W. Wu, K. Liu, and X. Tang, “Preliminary study on the antitumor immuno-protective mechanism of β-elemene,” Chinese Journal of Oncology, vol. 21, no. 6, pp. 405–408, 1999. View at Google Scholar · View at Scopus
  10. X. Li, G. Wang, J. Zhao et al., “Antiproliferative effect of β-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2-M phase,” Cellular and Molecular Life Sciences, vol. 62, no. 7-8, pp. 894–904, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. X. S. Wu, T. Xie, J. Lin et al., “An investigation of the ability of elemene to pass through the blood-brain barrier and its effect on brain carcinomas,” Journal of Pharmacy and Pharmacology, vol. 61, no. 12, pp. 1653–1656, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. W. D. Figg, P. Arlen, J. Gulley et al., “A randomized phase II trial of docetaxel (taxotere) plus thalidomide in androgen independent prostate cancer,” Seminars in Oncology, vol. 28, supplement 15, no. 4, pp. 62–66, 2001. View at Google Scholar · View at Scopus
  13. Y. Sun, L. J. Shan, Y. J. Liu, and X. N. Cui, “The effect of cinobufacini injection on DNA topoisomerase I of human hepatocellular carcinoma HepG-2 cells,” Chinese Journal of Oncology, vol. 19, no. 6, pp. 410–413, 2010. View at Google Scholar
  14. S. Belluti, V. Basile, P. Benatti, E. Ferrari, G. Marverti, and C. Imbriano, “Concurrent inhibition of enzymatic activity and NF-Y-mediated transcription of Topoisomerase-IIα by bis-DemethoxyCurcumin in cancer cells,” Cell Death and Disease, vol. 4, no. 8, article e756, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. D. Perrin, B. van Hille, J.-M. Barret et al., “F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action,” Biochemical Pharmacology, vol. 59, no. 7, pp. 807–819, 2000. View at Publisher · View at Google Scholar · View at Scopus
  16. W. A. Denny and B. C. Baguley, “Dual topoisomerase I/II inhibitors in cancer therapy,” Current Topics in Medicinal Chemistry, vol. 3, no. 3, pp. 339–353, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. W. Fayad, M. Fryknäs, S. Brnjic, M. H. Olofsson, R. Larsson, and S. Linder, “Identification of a novel topoisomerase inhibitor effective in cells overexpressing drug efflux transporters,” PLoS ONE, vol. 4, no. 10, Article ID e7238, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. S. Squires, A. J. Ryan, H. L. Strutt, P. J. Smith, and R. T. Johnson, “Deoxyguanosine enhances the cytotoxicity of the topoisomerase I inhibitor camptothecin by reducing the repair of double-strand breaks induced in replicating DNA,” Journal of Cell Science, vol. 100, no. 4, pp. 883–893, 1991. View at Google Scholar · View at Scopus
  19. X. Huang, H. D. Halicka, F. Traganos, T. Tanaka, A. Kurose, and Z. Darzynkiewicz, “Cytometric assessment of DNA damage in relation to cell cycle phase and apoptosis,” Cell Proliferation, vol. 38, no. 4, pp. 223–243, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. Q. Q. Li, G. Wang, M. Zhang, C. F. Cuff, L. Huang, and E. Reed, “β-Elemene, a novel plant-derived antineoplastic agent, increases cisplatin chemosensitivity of lung tumor cells by triggering apoptosis,” Oncology Reports, vol. 22, no. 1, pp. 161–170, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. G. del Bino, J. S. Skierski, and Z. Darzynkiewicz, “Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells,” Cancer Research, vol. 50, no. 18, pp. 5746–5750, 1990. View at Google Scholar
  22. W. Gorczyca, J. Gong, B. Ardelt, F. Traganos, and Z. Darzynkiewicz, “The cell cycle related differences in susceptibility of HL-60 cells to apoptosis induced by various antitumor agents,” Cancer Research, vol. 53, no. 13, pp. 3186–3192, 1993. View at Google Scholar · View at Scopus
  23. O. Sordet, Q. A. Khan, and Y. Pommier, “Apoptotic topoisomerase I-DNA complexes induced by oxygen radicals and mitochondrial dysfunction,” Cell Cycle, vol. 3, no. 9, pp. 1095–1097, 2004. View at Google Scholar · View at Scopus